🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

“I guess I got it all started… but I didn’t know about it until I was 58.” – Norma In the latest episode of our Living with Netherton video series, we meet Norma Coles, a 79-year-old woman whose life with Netherton Syndrome (NS) began long before the condition had a name. For

Quoin Pharmaceuticals $QNRX will be announcing its first quarter financial results on Tuesday, May 13th. Read more here: bit.ly/44pgGJh #investors

.Quoin Pharmaceuticals is pleased to announce strong first quarter results for 2025 that included continued progress and multiple breakthroughs of our lead asset QRX003 for the treatment of Netherton Syndrome. Read more here: bit.ly/44BW8xg #investors

.Quoin Pharmaceuticals $QNRX is pleased to announce Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study. Read more here: finance.yahoo.com/news/quoin-pha… #investors

.Quoin Pharmaceuticals $QNRX announced lead candidate QRX003 has received Orphan Drug Designation from the European Medicines Agency (EMA) for the treatment of Netherton Syndrome. We continue to make important clinical and regulatory progress for QRX003 as a potential treatment for

.Quoin Pharmaceuticals $QNRX has announced another important and significant milestone receiving U.S. FDA clearance to initiate its second pivotal clinical study, CL-QRX003-002, for the treatment of Netherton Syndrome using QRX003. Quoin is the only company conducting two late-stage

.Quoin Pharmaceuticals $QNRX has secured FDA Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome. The Quoin team is fully focused on completing our pivotal clinical studies and advancing QRX003 towards a New Drug Application as the first potential treatment for this

.Quoin Pharmaceuticals has released its third video for its NETHERTON NOW campaign showcasing Professor Jemima Mellerio, a globally recognized expert in genetic skin disorders. The video sheds light on the severe impact of Netherton Syndrome, particularly in infants and young children,

Failure to Thrive in Netherton Syndrome: A Critical Pediatric Concern Infants with Netherton Syndrome (NS) often face life-threatening challenges in their earliest days. Beyond the hallmark symptoms of fragile, peeling skin and persistent erythroderma, many experience failure to

Quoin Pharmaceuticals $QNRX announced today a comprehensive update on its development pipeline. Lead candidate QRX003 continues to advance in two active registrational clinical studies for Netherton Syndrome. We remain on track to file an NDA in the second half of 2026. Positive

Quoin Pharmaceuticals $QNRX will announce its second quarter financial results, next Thursday, August 7th.Read more here: bit.ly/4mmAPW6

.Quoin Pharmaceuticals $QNRX is pleased to announce strong second quarter results for 2025, highlighted by continued clinical progress and key regulatory milestones for our lead asset QRX003 for the treatment of Netherton Syndrome, as well as expanding development efforts across our